Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obinutuzumab + pixantrone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Obinutuzumab + pixantrone is a combination therapy evaluated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other aggressive lymphomas. Obinutuzumab is a type II glycoengineered anti-CD20 monoclonal antibody that targets the CD20 antigen on B cells, leading to cell death through direct cytotoxicity and immune-mediated mechanisms. Pixantrone is an aza-anthracenedione antineoplastic agent that acts primarily as a DNA intercalator and topoisomerase II inhibitor, causing double-stranded DNA breaks and cell death. The combination has shown clinical activity in heavily pretreated patients with relapsed/refractory DLBCL, but failed to meet its primary endpoint in phase II trials. Both agents have demonstrated individual benefit in aggressive lymphomas; their combination aims to improve outcomes for patients with limited options[3][4][7].
- Brand names
- Gazyva (for obinutuzumab)Pixuvri (for pixantrone)
- Other names
- None
02
Targets
Beyond the preview
Go deeper on Obinutuzumab + pixantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Obinutuzumab + pixantrone.